501 Reasons to Use Good Life Labs Oral Chelating Formula

501 studies citing the benefits, effectiveness, and safety of EDTA Chelating Therapy

1. Toyota H, Shibata S (Kyoto University). Supplementary studies on pharmacology of disodium ethylenediaminetetraacetate (EDTA salt). Nippon Yakuriguku Zasshi. 1956;52:1-9. (CA51:11567e)

2. Uhl HSM, Brown HH, Zlatkis A, Zak, B, Myers GB, Boyle AJ. Effect of ethylenediamine-tetraacetic acid (EDT) on cholesterol metabolism in man. Preliminary report of effect of parenteral and oral administration of disodium and calcium salts. Am J Clin Pathol. 1953; 23:1226-1233. (CA48:2257d)

3. Vasil'eva OG. (Inst Ind Hyg Occup Dis, Acad Med Sci, USSR) Side effects of CaNa2 ethylene-diaminetetraacetate in experimental lead intoxication. Gigiena 1 Sanitariya. 1961;26:22-5 (Mar.). (979)

4. Vozar L. Complexons in food products and their effect on the metabolic processes. Prumysl potravin. 1958; 9:649-653. (CA53:8461i)

5. Vozar L. Effect of complexon III on the distribution of calcium and phosphorus in bones. Biologia. 1958; 13:695-699. (CA55:5762e)

6. Williams JD, Leigh DA. (Edgware General Hospital) Lead poisoning. Letters to the editor. British Med J. 1964; 1:1511 (June 6). (2841)

7. Williams JD, Matthews GA, Judd AW. (St. Paul's Hospital) Oral calcium disodium versenate in treatment of lead poisoning. British J Ind Med. 1962; 19-211-215 (July). (2491)

8. Windsor E, Cronheim GE (Riker Labs, Inc.). Gastrointestinal absorption of heparin and synthetic heparinoids. Nature. 1961; 190:203-204. (CA55:23818a) [Heparin Na U.S.P. and the K salt of sulfopolyglucin can be absorbed from the gastrointestinal tract when given orally with an alk. salt of ethylenediaminetetraacetic acid (I). The chelation of Ca and (or) Mg ions by I may be involved.]

9. Windsor E (to Riker Laboratories). Orally active therapeutic compositions, especially polysaccharide sulfates. U.S. 3,088,868 (Cl 167-55). May 7, 1963, Appl Aug. 18, 1958. (CA59:12598d)

10. Wynn JE, Van't Riet B, Borzelleca JF (Med. Coll. of Virginia). Toxicity and pharmaco-dynamics of EGTA: oral administration to rats and comparisons with EDTA. Toxicol Appl Pharmacol. 1970; 16(3):807-817. (CA73)

11. Yang SS. Toxicological investigations of ethylenediaminetetraacetic acid. Dissertation. Univ. Mass. 1952:94 p.

12. Rieders F, Copeland JE (Jefferson Med Coll). Inhibition of accumulation of chronically ingested lead in rats by simultaneous feeding of edathamil calcium disodium (Na2CaEDTA). Federation Proceedings. 1956; 15:Abstract No. 1541 (Mar.). (693)

13. Schuttmann C, Schuttmann W (Inst. Of Occup Med, Berlin-Lichtenberg). The medical prevention of occupational lead poisoning by oral administration of calciumdinatrium ethylenediaminetetraacetate. Zeitschrift fur Arztliche Fortbildung. 1963; 57:1301-1307 (Dec.). (2621)

14. Shiels DO, Thomas DLG, Kearley E. Treatment of lead poisoning by edathamil calcium-disodium. AMA Arch of Ind Health. 1956; 13:489-498 (May). (1718)

15. Savicevic M, Petrovic L. Prevention of industrial lead poisoning. Vojnosanitetski Pregled. 1962; 19:531-535 (July-Aug.). (3191)

16. Salvini M (Univ. Padua). The calcium chelate of disodium ethylenediamine tetraacetate in the treatment of saturnism. Folia Medica (Naples). 1955; 38:2:111-126. (1616)

17. Saruta N, Yamaguchi S. A new diagnostic method of occupational lead poisoning for group inspection. J Sci of Labour (Japan). 1957; 33:540 (July). (1855)

18. Ritter J, Dacquet J (Inst. Hyg. Rabat, Morocco). Detection and ambulatory treatment of lead poisoning by oral administration of calcium di-sodium versenate. Maroc Medical. 1961; 40:377-382 (Apr.). (2323)

19. Remy R (Inst. Physiol. Vet. Coll.). Experimental studies on lead poisoning in animals. I. Toxicology. II. Therapy and prophylaxis. Deutsche Tierurztliche Wochenschrift. 1956; 63:385-388; 405-408 (Oct. 1; 15). (692)

20. Pott R. Control of lead exposure as practiced in a lead foundry. Zentralplatt fur Arbeltsmedizin Arbeitsschutz. 1961; 11:211-214 (Sept.). (2317)

21. Pott R. Is prophylaxis of lead poisoning with EDTA possible? Archiv fur Gewerbe-pathologie Gewerbehygiene. 1959; 17:4:354-364. (2053)

22. Pettinati L, Gribaudo C, Rasetti L. Oral and intravenous versenate in the therapy of chronic lesions caused by lead. Minerva Medica. 1962; 53:2092-2097 (July). (2458)

23. Pendergrass JC. The effects of the chronic ingestion of low levels of inorganic mercury(11) and mercury(11) complexed with EDTA on the rodent neuronal cytoskeleton: possible role of these forms of environmental mercury exposure in the etiology of Alzheimer's disease. Diss Abstr Int B (Avail. Univ. Microfilms Int., Order No. DA9527428. 1975; 1995:56(4). (CA)

24. Oser BL, Oser M, Spencer HC. Safety evaluation studies of calcium EDTA. Toxicol Appl Pharmacol. 1963; 5:142-162. (CA59: 9223a)

25. Moeschlin S. The clinical picture and therapy of lead poisoning. Zeitschrift fur Unfallmedizin Berufskrankheiten 51. 1958; 2:129-149. (1936)

26. Myslak Z, Buczkowski M. The effect of calcium versenate (Ca-EDTA) on the kidney in the treatment of lead poisoning. Polskie Archiwum Medycyny Wewnetrznej. 1961; 31:853-856. (2304) [Kidney function tests (creatinine clearance, RN) were carried out on 20 out of 120 cases of chronic Pb poisoning treated by oral administration of CaEDTA. The results showed no harmful effect of EDTA on the kidneys during treatment.]

27. Myslak Z. Treatment of chronic saturnism by oral administration of calcium versenate. Medycyna Pracy. 1960; 11:353-368. (2169)

28. Nakaue HS, Thomas JM, Reid BL. Comparison of EDTA, terephthalic acid, sodium sulfate and acetyl-salicylic acid as antibiotic potentiating agents in broiler chicks. Poultry Sci. 1967; 46:417-421. (NA38)

29. Vozar L. Relation between peroral application of complexon 3 (ethylenediaminetetraacetic acid disodium salt) and the activity of alkaline phosphatase of blood serum. Biologia. 1960; 15:208-211. Z Inn Med. 1959; 14:676. (CA54:25290h)

30. Thomsen MK, Jacobsen C, Skibsted L II. Mechanism of initiation of oxidation in mayonnaise enriched with fish oil as studied by electron spin resonance spectroscopy. Eur Food Res Technol. 2000; 211(6):381-386. (CA)

31. Sidbury JB Jr., Bynum JC, Fetz LL. (US Public Health Serv.) Effect of chelating agent on urinary lead excretion. Comparison of oral and intravenous administration. Proceedings of Soc Experimental Biol and Med. 1953; 82:226-228. (1444)

32. McMahon FG. Comparison of the effect of Fe 3-specific (N, N-dihydroxyethylglycine), versenol, and calcium disodium versenate on urinary iron excretion in a patient with hemochromatosis. J Lab Clin Med. 1956; 48:589-602. (CA51:3027c)

33. McPhail AP, Patel RC, Bothwell TH, Lamparelli RD. EDTA and the absorption of iron from food. Amer J Clin Nutr. 1994; 59(3):644-648. (NA64)

34. Manville IA, Moser R. Recent developments in the care of workers exposed to lead. The effect of the calcium chelate of disodium ethylenediamine-tetraacetic acid on led in the blood and urine of battery workers. AMA Arch Ind Health. 1955; 12:528-538 (Nov.). (1587)

35. Heimbach J, Rieth S, Mohamedshah F, Slesinski R, Samuel-Fernando P, Sheehan T, Dickmann R, Borzelleca J. Safety assessment of iron EDTA (sodium iron (Fe3+) ethylenediaminetetraacetic acid): summary of toxicological, fortification and exposure data. Food Chem Toxicol. 2000; 38(1):99-111. (CA) [A review with many refs. Iron EDTA

36. Davidsson L, Kastenmayer P, Hurrell RF. Sodium iron EDTA (NaFe(III)EDTA) as a food fortification: the effect on the absorption and retention of zinc and calcium in women. Amer J Clin Nutr. 1994; 60(2):231-237. (NA64)

37. Foreman H, Trujillo TT. Metabolism of carbon14-labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med. 1954; 43:566-571. (CA48: 8949a)

38. Foreman H. The pharmacology of some useful chelating agents. Metal Binding Med, Proc Symposium, Philadephia 1959. 1960; 82:94. (CA54:17719e)

39. Bradley JE, Powell AM Jr. Oral calcium EDTA in lead intoxication of children. J Ped. 1954; 45:297-301 (Sept.). (2882)

40. Capellaro F, Galdo PC, Alliod R. Possibility of treating saturnism by versenate by the oral route. Minerva Medica. 1963; 54:474-477. (2508)

41. Calabrese A, Astolfi E, Mariani F. Oral treatment of lead intoxication with calcium versenate. Clinical and experimental study. Dia Medico. 1961; 33:2292-2294 (Oct. 5). (2239)

42. Cotter LH. Treatment of lead poisoning by chelation. JAMA. 1954; 155:906-908. (CA52:10388a)

43. Choie DD, Copley MP, Gindhart TD. Mitigation of intestinal cytotoxicity of cisplatin by EDTA in rats. Cancer Lett. 1983; 19(2):195-198. (CA)

44. Cohn SH. The effect of chemical agents on the skeletal content and excretion of internally deposited fission products. US Atomic Energy Comm. ANL-5584. 1956; 144-149. (CA51:4557f)

45. Flanagan PR, Chamberlain MJ, Valberg LS. The relationship between iron and lead absorption in humans. Am J Clin Nutr. 1982; 36(5):823-9. (CA)

46. Forbes RM. Excretory patterns and bone deposition of zinc, calcium, and magnesium in the rat as influenced by zinc deficiency, EDTA, and lactose. J Nutr. 1961; 74:194-200. (CA59:7921b)

47. Davidson L, Almgren A, Hurrell RF. Sodium iron EDTA (NaFe(III) EDTA) as a food fortificant does not influence absorption and urinary excretion of manganese in healthy adults. J Nutr. 1998; 128(7): 1139-1143. (CA)

48. Desoille H, Albahary C, Truhaut R, Boudene C. The lead mobilization test using CaNa2EDTA. XII Intern Cong Occup Health. Helsinki, Finland. 1957; Vol. 111, Proceedings, pp. 287-290. (1773)

49. Davies NM, Jamali F. Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers. Hum Exp Toxicol. 1997; 16(7):345-349. (CA)

50. Kalz F, Quastel J II, Telner P, Schafer A, MacIntyre W. Changes in the electrophoretic patterns of the serums of psoriatics under various forms of therapy. J Invest Dermatol. 1958; 31:161-166. (CA53:20529a)

51. Kehoe RA. Misuse of edathamil calcium-disodium for prophylaxis of lead poisoning. J Amer Med Assoc. 1955; 157:341-342 (Jan. 22). (1582)

52. Mariani B, Bisetti A, Romeo V. Blood-cholesterol-lowering action of the sodium salt of calciumethylenediaminetetraacetic acid. Gazs Intern Med Chir. 1957; 62:1812-1823. (CA51:16953c) [Two g. daily of the drug, in 2 intravenous administrations, or (with a lower effect) by mouth or rectum, caused in humans a decrease of blood cholesterol, especially of its free fraction.]

53. Stankovic M, Petrovic LJ, Poleti D (Inst. Public Health, Belgrade, Serbia). A contribution to the laboratory diagnostics of early saturnism. Arhiv za Higijenu Rada 1 Toksikologiju. 1962; 13:189-194. (2480)

54. Srbova J, Telsinger J (Clinic Occup. Dis., Prague). Absorption of calcium disodium salt of ethylenediaminetetraacetic acid after oral administration in the treatment of lead poisoning. Archiv fur Gewerbepatholgie und Gewerbehygiene 15. 1957; 6:572-580. (1858)

55. Suenaka T, Kosaka H, Miyama K, Tabuchi T, Hirata M, Hara I, Masumoto D, Akaboshi S (Osaka Prefect Inst. Public Health, Osaka). The effects of repeated oral administration of calcium-EDTA on patients with chronic lead poisoning. Osaka-furitsu Koshu Eisei Kenkyusho Kenkyu Hokoku, Rodo Eisei Hen. 1979; 17:1-9. (CA)

56. Suenaka T, Miyajima K, Kosaka H, Tbuchi T, Hara I. Urinary excretion of heavy metals following oral administration of calcium EDTA. Osaka furitsu Koshu Eisei Kenkyusho Kenkyu Hokoku, Rodo Eisei Hen. 1976; 14:19-23. (CA)

57. Swenerton H, Hurley L S (Dept. Nutr. Univ. Calif., Davis, Calif.). Teratogenic effects of a chelating agent and their prevention by zinc. Science. 1971; 173 (3991), 62-64 (Eng). (CA75)

58. Telsinger J, Srbova J. Effect of D-penicillinamine on the urinary excretion of mercury and lead. Pracovni Lekarstvi 16. 1964; 10:433-435. (2827) [Seven patients with chronic Pb poisoning were treated with daily oral doses of 150 mg D-penicillinamine for 4-7 days. Urinary excretion of Pb increased about 4-fold which is practically as much as after administration of 0.5-g tablets of CaEDTA, 4 times/day. If future studies confirm its lower toxicity in long-term administration, D-penicillinamine may replace EDTA.]

59. Tripod J. General pharmacodynamic aspects of mobilizing iron with chelators. Atti Acad Med Lombarda, Suppl 20. 1965; 2025-2027. (CA67)

60. Tufft LS, Nockels CF. The effects of stress, escherichia coli, dietary ethylenediamine-tetraacetic acid, and their interaction of tissue trace elements in chicks. Poult. Sci. 1991; 70(12):2439-2449. (CA)

61. Tolot F, Jaquis GM, Soubrier R, Bresson JR. Lead mobilization in, and the &-aminolevulinic acid (ALA) content of the urine of lead-exposed subjects. Egesesegiudomany. 1966; 10(4):375-380. (CA66)

62. Tolot F, Jaquis GM, Soubrier R, Bresson JR. The use of chelating agents "per os" in the treatment of prophylaxis of lead poisoning. Proceedings of the Society of Ind Med at Lyon. 1962; 23:376-379 (June). (2484)

63. Perrault M. Truhaut R, Klotz B, Boudene C, Dreux C, Clavel B, Chain F. The effectiveness of CaEDTA, in occupational lead poisoning. Archiv des Maladies Professionelles de Medecine du Travail et de Securite Sociale. 1956; 17:423-429; discussion 470-472. (1702)

64. Mitchell Jr PH, Schroeder HA. Depression of cholesterol levels in human plasma following ethylenediamine tetracetate and hydralazine. J Chron Dis. 1955; 2:520-533. (CA54:18787i)

65. Prasad T, Chhabra A, Atreja PP. Effect of feeding chelating agent (EDTA) on trace mineral balances in goats. Indian J Dairy Sci. 1994; 47(3):219-221. (CA)

66. Rodriguez A. Substances that potentiate the absorption of vitamin B12 administered orally. Anales Inst. Farmacol. Espan. 1961; 9-10, 57-61. (CA61:2373a)

67. Rotta C, Parigi A. Prevention of lead intoxication by oral administration of calcium versenate. Med del Lavoro. 1961; 52:769-779 (Dec.). (2325)

68. Saita G, Moreo L. Lead and porphyrins in the bile of patients with lead poisoning treated with calcium versenate. Med del Lavoro. 1958; 49:376-384 (May). (1956)

69. Scadding G, Bjarnason I, Brostoff J, Levi AJ, Peters TJ. Intestinal permeability to 51CR-labelled ethylenediaminetetraacetate in food-intolerant subjects. Digestion. 1989; 42(2):104-109. (NA59)

70. Sidbury Jr JB. Lead poisoning, treatment with disodium calcium ethylenediamine-tetraacetate. Am J Med. 1955; 18:932-946 (June). (1622)

71. Bersworth Chemical Co. The versenes for exacting chemical control of cations in solution. Technical Bulletin No. 2, 4th ed. 1952; 102 pp. (1313)

72. Berti T. Pharmacological investigation on sodium bismuth ethylenediaminetetraacetate (Bi-EDTA). Arch Ital. Sci. Farmacol. 1956; 6:293-298. (CA51:9939h)

73. British Industrial Biological Research Association. The metabolism of EDTA. Food and Cosmetics Toxicol. 1964; 2:741-745 (Dec.). (2670)

74. Gervais MJ. The medical prevention of lead poisoning in an electrolytic zinc factory. Montpellier Medical. 1962; 61:12-27 (Jan.). (2401)

75. Jugo S, Maljkovic T, Kostial K. Influence of chelating agents on the gastrointestinal absorption of lead. Toxicol. Appl. Pharmacol. 1975; 34(2):259-263. (CA)

76. Teisinger J, Zumanova R, Zezula I. Effect of calcium salt of ethylenediaminetetraacetic acid on the binding of lead by erythrocytes and blood proteins. Pracovni lekufstvi. 1957; 9:277-280. (CA52:9447g)

77. Stancev S. Prophylaxis of chronic lead poisoning by oral administration of CaNa2EDTA. First National Congress of Industrial Health. Abstracts of papers. 1963; 37-38. (2634)

78. Taucin EJ, Svilane ABV. Effect of EDTA and chlortetracycline on assimilation of trace elements by chickens. Fiziologiceski aktivnye komponenty pitanija zivotnyh. 1969; 163-170 Russian. (NA41)

79. Suenaka T, Miyajima K, Kosaka H, Tabuchi T, Hara I. Urinary excretion of heavy metals following oral administration of calcium-EDTA. Osaka-furitsu Koshu Eisei Kenkyusho Kenkyu Hokoku, Rodo Eisei Hen. 1977; 15:27-31. (CA) [Ca EDTA, administered to workers dealing with Pb, significantly increased Pb and Zn excretion in urine. There was a high correlation between urinary total metal and Zn concns.]

80. Nishino S. Effect of oral administration of calcium ethylenediaminetetraacetate in lead poisoning. Kokumin Eisel. 1957; 26:90-95. (1834)

81. Nottbohm L. The supervisory physician in plants presenting lead hazards. Medizinische Welt. 1963; 44:224-228. (2596)

82. Pagnotto LD, Elkins HB, Bayka I. Oral administration of edathamil calcium disodium (calcium disodium versenate). AMA Archives of Ind. Health. 1958; 17:29-33 (Jan.). (P1943)

83. Parigi A, Rasetti L. Action of orally administered CaEDTA on the metabolism of the porphyrinic precursors in lead poisoning. Lavoro e Medicina 16. 1962; 3:44-50. (2452)

84. Peters HA, Eichman PL, Price JM, Kozelka FL, Reese HH. Abnormal copper and trytophan metabolism and chelation therapy in anticonvulsant drug intolerance. Diseases Nervous System. 1966; 27(2):97-107. (CA64:16509c)

85. Petrovic LJ, Stankovic M, Savicevic M, Poleti D. Our experiences with calcium disodium edathamil. Proc. 13th Int. Congr. on Occup. Health July 25-29, 1960. 1961; pp 338-341. (2176)

86. Pilat L, Moscovici B, Iorga M. CaNa2EDTA treatment in mercury intoxication. Proc. 13th Int. Congr. Occup. Health, 1960. 1961; p. 341-343.

87. Prevot PA, Sulotto F, Poli G, Parigi A. Environmental lead pollution and the principal biological indexes for evaluating the risk of lead poisoning. Lav. Um. 1969; 21(5):200-209. (CA72)

88. Reinl W. Prophylaxis of lead workers with orally administered Ca2EDTA. Zentralblatt fur Arbeitsmedizin und Arbeitsschutz. 1956; 6:5-8 (Jan.). (1709)

89. Reinl W. Modern therapy of lead intoxication. Regensburger Jahrbuch fur Hrztliche Fortbildung. 1959/60; 8:(8 pp). (2184)

90. Roxburgh RC, Haas L. The diagnostic importance of glycosuria in lead poisoning in childhood. Arch Dis in Childhood. 1959; 34:70-73 (Feb.). (2957)

91. Selander S. Treatment of lead poisoning. A comparison between the effects of sodium calcium-edetate and penicillamine administered orally and intravenously. Brit J Indust Med. 1967; 24:272-281.

92. Bell RF, Gilliland JC, Boland JR, Sullivan BR. Effect of oral edathamil calcium-disodium on urinary and fecal lead excretion. Comparative excretory studies with intravenous therapy. AMA Arch Ind Health. 1956; 13:366-371 (Apr.). (1642)

93. Bersworth FC, Rubin M. Prophylactic calcium chelate compositions for heavy metal poisoning. U.S. Patent. 1959; 1,875,129 (Feb. 24), to Dow Chemical Co. From Chemical Abstracts 53:10672. (1982)

94. Bersworth FC, Rubin M. Organo-metallic detoxicants. U.S. Patent. 1955; 2,698,823 (Jan. 4) to F.C. Bersworth. From Chemical Abstracts 49:Abst. No. 4244. (1552)

95. Bjarnason I, Peters TJ, Veall N. A persistent defect in intestinal permeability in coeliac disease demonstrated by 51Cr-labelled EDTA absorption test. Lancet. 1983; 1:323-325.

96. Blomquist L, Bark T, Hedenborg G, Norman A. Evaluation of lactulose/mannitol and 51Cr-ethylenediaminetetraacetic acid/14C-mannitol methods for intestinal permeability. Scand. J Gastro. 1997; 32(6):805-812. (BA 104)

97. Blumer W, Reich T. Leaded gasoline - A cause of cancer. Environment Int. 1980; 3:465-471.

98. Blumer W. Calcium-disodium-EDTA treatment for cardiovascular symptoms. Plzen Lek Sborn Suppl. 1990; 62:157-159.

99. Cann HM, Verhulst HL. Edathamil calcium-sodium (EDTA) in lead poisoning. Tennessee Ind. Hygiene News 15. 1958; 1:3-4. (2936)

100. Cho SS, Mejia L, Morel L, Samuel-Fernando P. Cooked cereal ingredient-containing products fortified with EDTA/iron compositions and methods for use. PCT Int. Appl. WO 99 05,920, 1999, US Appl. 54,428 1997, 24 pp. (CA)

101. Cowan TKJ, Phillips GD, Bragg DB. Effect of dietary EDTA on the ability of chicks to tolerate sodium chloride in the water. Canadian J Animal Sci. 1971; 51(3):633-637. (NA42)

102. Engstroem B, Norin H, Jawait M, Ingman F. Influence of different cadmium-EDTA complexes on distribution and toxicity of cadmium in mice after oral or parenteral administration. Acta Pharmacol. Toxicol. 1980; 46(3):219-234. (CA)

103. Gehres RF, Raymond S. A new chemical approach to the solution of urinary calculi. J Urol. 1951; 65:474-483. (CA47:8241c)

104. Greig JB. Sodium iron ethylenediamine tetraacetic acid (EDTA). WHO Food Addit. Serv. 2000; 44:105-111 (Safety Evaluation of Certain Food Additives and Contaminants). (CA) A review with 9 refs. on toxicity of NaFeEDTA, including acute and short-term toxicity, genotoxicity, developmental toxicity and food and nutritional toxicity.

105. Harishima S, Tsuchiya K, Kondo H, Motouchi M, Sakaguchi T, Mori A. Therapy and prevention of lead poisoning with calcium versenate. Keio J. Med. 7. 1958; 93-105. (1914)

106. Hathcock JN, Hill CH, Matrone G. Vanadium toxicity and distribution in chicks and rats. J. Nutr. 1964; 82(1):106-110. (CA60:12576g)

107. Hurrell RF, Ribas S, Davidsson L. NaFe3+EDTA as a food fortificant: influence on zinc, calcium and copper metabolism in the rat. British J Nutr. 1994; 71(1):85-93. (NA64)

108. Kojima S, Kiyozumi M, Matsumoto S, Yamamoto M, Nakamura C, Niho K. Studies on poisonous metals. III. Effects of chelating agents on gastrointestinal absorption, distribution, and excretion of cadmium chloride in rats. Eisei Kagaku. 1977; 23(1):43-47. (CA)

109. Krari N, Allain P. Effects of three chelating agents, EDTA, NTA, and TPP, on the concentration of elements in rat tissues. Biol. Trace Elem. Res. 1991; 29(2):125-131. (CA)

110. Makashev KK. Effect of calcium and disodium salts of ethylenediaminetetraacetic acid on lead absorption, accumulation, and excretion from the system after lead intoxication. Trudy Inst Kraevol Patologil, Akademiya Nauk Kazakhskoi SSR. 1962; 10:180-189. (1008)

111. Madsen JL, Scharff O, Rabol A, Krogsgaard OW. Relationship between small-intestinal transit rate and intestinal absorption of 14C-labelled mannitol and 51Cr-labelled ethylenediamine-tetraacetic acid in healthy subjects. Scand. J Gastro. 1996; 31(3):254-259. (NA66)

112. MacPhail AP, Bothwell TH, Torrance JD, Derman DP, Bezwoda WR, Charlton RW, Mayet F. Factors affecting the absorption of iron from Fe(III)EDTA. British J Nutr. 1981; 45(2):25-227. (NA52)

113. Merville R, Dequidt J, Fontaine G. Ambulatory treatment of occupational lead poisoning by calcium disodium edetic acid. Lille Med. 4. 1959; 5:291-293. (2035)

114. Stankovic M, Petrovic LJ, Poleti D. Application of Ca2EDTA (dicalcium ethylenediamine-tetraacetate) for the diagnosis of lead poisoning. Acta Pharm. Jugoslav. 1960; 10:155-159. (2202) The compound was administered orally to 24 printers, 18 persons with severe Pb poisoning, and 8 controls with no Pb exposure. The upper limit of Pb excretion in urine after 3 g CaEDTA was 0.340 mg/24 hr.

115. Suso FA, Edwards Jr HM. Influence of various chelating agents on absorption of cobalt-60, iron-59, manganese-54, and zinc-65 by chickens. Poultry Sci. 1968; 47(5):1417-1425. (CA70)

116. Vozar L. The action of complexon 3 on the copper balance and level in the organism after oral administration. J'harmazie. 1959; 14:459-466. (CA54:7892d)

117. Nielsen FH, Sunde ML, Hockstra WG. Effect of some dietary synthetic and natural chelating agents on the zinc-deficiency syndrome in the chick. J Nutr. 1966; 89(1):35-42. (CA65:14176h)

118. Pedinelli M, Stringari M. Observations on the treatment "per os" with chelating agents in tetraethyl lead production workers. Rassegna di Medicina Industriale. 1959; 28:514-525 (Nov.-Dec.) (2048)

119. Preda N, Niculescu T, Rafaila E. The treatment of lead intoxication with chelating agents. Igiena (Bucharest)13. 1964; 3:233-242. (2784) Treatment of Pb-poisoned patients in the Clinic for Occupational Diseases, Bucharest, with iv injections of 2 g CaNa2EDTA/day for 2-20 days markedly increased urinary excretion of Pb. Oral doses of 4-6 g EDTA/day were less effective.

120. Sapeika N. Actions of lead ethylenediaminetetraacetic acid (EDTA) complex. Arch. Intern. Pharmacodynamie. 1955; 101:488-494. (CA49:14168e)

121. Savicevic M, Petrovic LJ. New views on the treatment of occupational lead poisoning. Vojnosanitetski Pregled. 1964; 21:173-177. (2804)

122. Svicevic M, Petrovic L, Stankovic M, Djordjevic S. Experiences with CaNa2EDTA (mosatil bayer) in chronic Pb exposure. Zentralblatt fur Arbeitsmedizin und Arbeitsschutz. 1959; 9:6-12 (Jan.) (2062)

123. Rubin M. Design of chelates for therapeutic objectives. Fed. Proceed. 20, Suppl. 10. 1961; 2:149-157 (Sept.) (2327)

124. Rosenman RH, Smith MK. The effect of certain chelating substances, salts of ethylenediamine-tetraacetic acid (EDTA), upon cholesterol metabolism in the rat. J Clin. Invest. 1956; 35:11-19. (CA50:6676b)

125. Roldan M, Suarez CL, Perdomo GM, Camarero SC, Escobar CH. Study of intestinal permeability in celiac disease with 51 Cr-EDTA. Acta Gastroenterol Latinoam. 1994; 24:37-40.

126. Proescher F. Anti-coagulant properties of ethylene bisiminodiacetic acid. Proc. Soc. Exptl. Biol. Med. 1951; 76:619-620.

127. Pommier SA, Lapierre H, de Passille AM, Gariepy C. Control of the bioavailibility of iron in heavy veal production by different feeding management systems: use of Ca-EDTA as an iron chelating agent. Can. J Anim. Sci. 1995; 75(1):37-44. (CA)

128. Aamoth HL, Butt FJ. Maintaining food quality with chelating agents. Ann. N.Y. Acad. Sci. 1960; 88:526-531. (CA55:12687e) Ethylenediaminetetraacetic acid (EDTA) and its di- or tetra-Na salts alleviate a wide variety of problems caused by trace-metal ions in food products.

129. Ainsworth M, Eriksen J, Waever Rasmussen J, Schaffalitzky De Muckadell OB. Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. Scand. J Gastroenterol. 1989; 24:993-998.

130. Albahary C, Truhaut R, Boudene C. The diagnosis of lead poisoning following urinary elimination of lead induced by calcium disodium versenate. Archiv. Maladies Professionnelles de Med. Du Travail et de Securite Sociale. 1958; 19:121-131 (Mar.-Apr.). (1883)

131. Albahary C, Truhaut R, Boudene C. Lead poisoning and detoxication by calcium versenate: new observations. Archiv. Maladies Professionnelles de Med. Du Travail et de Securite Sociale. 1957; 18(1):40-46. (1739)

132. Bastenier H. Considerations on the diagnosis and treatment of occupational lead poisoning. Acta Clinica Belgica. 1963; 18:144-151. (2501)

133. Bartolozzi O, Zurlo N. Effects of the preventive treatment with calcium versenate in workers exposed to lead. Medicina del Lavoro. 1960; 51:607-611 (Oct.). (2094)

134 . Barnes WS, Weisburger JH. Formation of mutagens in cooked foods. VI. Modulation of mutagen formation by iron and ethylenediaminetetracetic acid (EDTA) in fried beef. Cancer Lett. 1984; 24(2):221-226. (CA)

135. Atkinson J, Vohra P, Kratzer FH. Effect of available dietary zinc on the utilization of protein by the chick and Japanese quail. Brit. J Nutr. 1972; 27(3):461-466. (CA77) [By using chicks and quail to measure net protein utilization (NPU) and true digestibility of N of isolated soybean protein and a mixt. of gelatin and casein in Zn-deficient diets, it was found that NPU for both was increased when the diets were supplemented with Zn or di-Na EDTA, as was the true digestibility of N of isolated soybean protein.]

136. Ashmead H, Mencimer FR. Methods for controlling and treating renal calculi. U.S. 3,281,322 (Cl. 167-55), Oct. 25, 1966. Appl. September 11, 1961. (CA66)

137. Basinger MA, Jones MM, Holscher MA, Vaughn WK. Antagonists for acute oral cadmium chloride intoxication. J Toxicol. Environ. Health. 1988; 23(1):77-89. (CA)

138. Ashmead H, Mencimer FR. Drugs for urinary calculi. U.S. 3,184,381 (Cl. 167-53), May 18, 1965. Appl. Feb. 28, 1961; 3 pp. (CA63:5459c)

139. Ashmead H, Mencimer FR. Drugs containing sequestering and chelating agents for preventing lithiasis and atherosclerotic plaques. Brit. 1,132,233 (Cl. A 61k) 30 Oct. 1968. Appl. 22 Oct. 1965, 21 pp. (CA70)

140. Bartolozzi O. Report of nine year of prophylactic treatment with calcium versenate in a storage battery plant. Medicina del Lavoro. 1964; 55:315-316 (Apr.). (2668)

141. Batskor IA, Timar M. The treatment of lead poisoning with CaEDTA per os. Egeszsegtudomany 5. 1961; 3:259-263. (2230)

142. Belknap EL, Perry MC. Treatment of inorganic lead poisoning with edathamil calcium-disodium. AMA Archiv. Ind. Hygiene Occup. Med. 1954; 10:530-547 (Dec.). (1463)

143. Batskor IA, Kovacs I, Pasceri I. The effectiveness of CaEDTA-treatment in the prophylaxis of lead intoxication. Zentralblatt fur Arbeitsmedizin Arbeitsschutz. 1961; 11:261-264 (Nov.) (2229)

144. Bonazzi P, Lanzoni J, Marcucci F, Mussini E. Pharmacokinetic studies of ethylenediamine-tetraacetic acid (EDTA) in rats. Eur. J Drug Metab. Pharmacokinet. 1981; 6:21-26.

145. Bickel H, Neale FC, Hall G. Clinical and biochemical study of hepatolenticular degeneration (Wilson's disease). Quart. J Med. 1957; 26:527-528. (CA52:3994f).

146. Blomquist L, Bark T, Hedenborg G, Svenberg T, Norman A. Scand. J Gastroenterol. 1993; 28:274-280.

147. Brykalski D, Wronowa B. The effect of oral administration of EDTA on the absorption and elimination of lead administered in the same manner. Medycyna Pracy 14. 1963; 4:313-320. (1044)

148. Brykalski D, Bolanowska W. Further studies on the effect of orally administered EDTA on lead absorption and excretion. Medycyna Pracy 15. 1964; 3:133-138. (1111)

149. Buescher R, Hamilton C. Protection of cucumber pickle quality of CaNa2 EDTA. J Food Qual. 2000; 23(4):429-441. (CA)

150. Brul S, Coote P. Preservative agents in foods. Mode of action and microbial resistance mechanisms. Int. J Food Microbiol. 1999; 50(1-2):1-17. (CA)

151. Byers RK. Review of the literature and report on 45 cases. Pediatrics. 1959; 23:585-603 (March). (2951)

152. Cranton EM. What about oral chelation. J Advancement Med. 1999; 12:237-239.

153. Comar C, Wasserman RH, Twardock AR, Lengemann FW. Effect of various substances on secretion of radiostrontium into milk. Health Phys. 1966; 12(12):1661-1669. (CA66)

154. David OJ, Hoffman SP, Sverd J, Clark J, Voeller K. Lead and hyperactivity. Behavioral response to chelation: a pilot study. Am. J Psychiat. 1976;133:1155-1158.

155. Foreman H. Use of chelating agents in treatment of metal poisoning (with special emphasis on lead). Fed. Proceed. 20, Suppl. 10. 1961; 2:191-196. (2256)

156. Food and Drug Administration, HHS (USA). Food additives permitted for direct addition to food for human consumption; calcium disodium EDTA and disodium EDTA. Fed. Regist. 2000; 65(153):48377-48379. (CA)

157. Freedman L, Blitz M, Sabine DB, Eigen E (to U.S. Vitamin & Pharmaceutical Corp.). Stable vitamin B12 solutions. U.S. 2,939,821, June 7, 1960. (CA54:20101i)

158. Escobar H, Perdomo M, Vasconez F, Camarero C, del Olmo MT, Suarez L. Intestinal permeability to 51Cr-EDTA and orocecal transit time in cystic fibrosis. J Pediat. Gastroenterol. Nutr. 1992; 14:204-207.

159. Dizon GD, Anselmo JE, Almonte JB, Aquino R, Navarro A. Study of health hazards in the storage battery manufacture in the Philippines. Excerpta Medica Foundation. 1964; Vol. III, pp. 1004-1010. (2688)

160. Edwards PJ, Morwood K. Pharmaceutical compositions against gastric disorders containing bacteriocins. PCT Int. Appl. WO 92 18,143 (Cl. A61K37/02), 29 Oct. 1992. GB Appl. 91/8,129, 15 Apr. 1991, 15 pp. (CA)

161. Domingo JL, Llobet JM, Corbella J. The effects of EDTA in acute cobalt intoxication in rats. Toxicol. Eur. Res. 1983; 5(6):251-255. (CA)

162. Eisenberg GM, Weiss W, Flippin HF. Effect of ethylenediaminetetraacetic acid and ascorbic acid on tetracycline blood serum concentrations. J Lab. Clin. Med. 1958; 52:895-898. (CA53:3499f)

163. Dunkley WL, Franke AA, Robb J, Ronning M. Influence of dietary copper and ethylenediamine-tetraacetate on copper concentration and oxidative stability of milk. J Dairy Sci. 1968; 51(6):863-866. (CA69)

164. Davin JC, Forget P, Mahieu PR. Increased intestinal permeability to (51 Cr) EDTA is correlated with IgA immune complex-plasma levels in children with IgA-associated nephropathies. Acta Paediat. Scand. 1988; 77:118-124.

165. De Freitas Tavares J, Porto AL. The use of chelating agents in the treatment of lead poisoning. Jornal do Medico (Porto). 1961; 44:925-929 (Apr. 29). (2250)

166. Davis PS, Deller DJ. Effect of orally administered chelating agents EDTA, DTPA, and fructose on radioiron absorption in man. Australas. Ann. Med. 1967; 16(1):70-74. (CA67)

167. Davidsson L, Walczyk T, Zavaleta N, Hurrell RF. Improving iron absorption from a Peruvian school breakfast meal by adding ascorbic acid or Na2EDTA. Am. J Clin. Nutr. 2001; 73(2):283-287. (CA)

168. Fritz JC, Pla GW, Boehne JW. Influence of chelating agents on utilization of calcium, iron and manganese by the chick. Poultry Sci. 1971; 50(5): 1444-1450. (CA75)

169. Gordon GF. EDTA and chelation therapy: history and mechanisms of action - an update. Clin. Pract. Altern. Med. 2001; 2:36-45.

170. Gordon GF. EDTA safe in treating patients with mercury toxicity. Townsend Lett. For Doctors & Patients. 1997; 163, 164:102.

171. Gordon G. Oral chelation for improved heart function. Life Enhancement. 1997 (Apr.); p. 7-15.

172. Gordon GF. Oral chelation: the other side of the story. Clin. Pract. Altern. Med. 2000; 1:113-115.

173. Gordon GF. Oral chelation with EDTA. J Holistic Med. 1986; 8:79-80.

174. Guepin J. A case of occupational lead poisoning. Ouest Metical. 1964; 17:570-573 (May 10). (2719)

175. Hutchinson HE, Stark JM. The anemia of lead poisoning. J Clin. Path. 1961; 14:548-549 (Sept.). (2277)

176. Horiuchi K, Noma H, Asano I, Hashimoto K. Studies on the industrial lead poisoning. An experimental study of lead intake in human beings through the respiratory tract. Osaka City Med. J 8. 1962; 2:151-169. (2413)

177. Hurrell RF, Reddy MB, Burri J, Cook JD. An evaluation of EDTA compounds for iron fortification of cereal based foods. Br. J Nutr. 2000; 84(6):903-910. (CA)

178. Hublet P. Comments relating to the preventive administration of EDTA for the prevention of lead poisoning. Third World Cong. On Prevention of Occup. Risks. 1961:492. (2275)

179. Itoh H, Yamaguchi T, Yamasawa S. Inhibition of hematopoietic action of iron by ethylene-diaminetetraacetate (EDTA). Yokohama Med. Bull 13. 1962; 1:9-16. (CA57:7863b)

180. Jenkins RT, Ramage JK, Jones DB, Collins SM, Goodacre RL, Hunt RH. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin. Invest. Med. 1988; 11:151-155.

181. Karunajeewa H. Influence of high calcium rearing diets, Christmas Island phosphate and ethylenediaminetetraacetic acid on the laying performance of White Leghorn X Australorp hens. Aust. J Exp. Agric. Anim. Husb. 1977; 17(89):944-948. (CA)

182. Karunajeewa H. Effect of some feed additives on the performance of broiler chicks fed diets containing high levels of meat and bone meal. Aust. J Exp. Agric. Anim. Husb. 1976; 16(82):685-690. (CA)

183. LaChance LE. Ingestion of ethylenediaminetetraacetic acid and the effect on life span of irradiated and control Habrobracon females. Nature. 1958; 182:870-871. (CA53:4587h)

184. Kimmel CA. Effect of route of administration on the toxicity and teratogenicity of EDTA in the rat. Toxicol. 1977; (40(2):299-306. (CA)

185. Leigh MJ, Miller DD. Effects of pH and chelating agents on iron binding by dietary fiber: implications for iron availability. Am. J Clin. Nutr. 1983; 38(2):202-213. (CA)

186. Lilis R, Fischbein A. Chelation therapy in workers exposed to lead. A critical review. JAMA. 1976; 235:2823-2824.

187. McGivern J, Mason J. The effect of chelation on the absorption of cadmium from rat intestine in vivo. J Comp. Pathol. 1979; 89(2):293-300. (CA)

188. Sprague G. The effect of dietary administration of ethylenediamine-tetraacetic acid upon the mineral content of mouse tissues. Trans. Nebr. Acad. Sci. 1976; 3:61-68. (CA)

189. Herta S. Studies of the effect of chelating agents in man. Ann. N.Y. Acad. Sci. 1960; 88:435-449. (CA55:2903c)

190. Sigthorsson G, Jacob M, Wrigglesworth J, Somasundaram S, Tavares I, Foster R, Roseth A, Rafi S, Mahmud T, Simpson R, Bjarnason I. Scand. J Gastroenterol. Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat. Scand. J. Gastroenterol. 1998; 33(7):728-735. (CA)

191. Solomons N, Viteri F, Pineda O, Jacob R. The effects of NaFeEDTA and ascorbic acid (AA) on zinc bioavailability in man. Fed. Proceed. 1979; 38(3, I):704. (NA49)

192. Sullivan TJ. Effects of metallic edetates on the growth and blood formation of rats. Arch. Intern. Pharmacodynamie. 1960; 124:225-236. (CA54:23068b)

193. Vohra P, Bond DC. The effect of various levels of dietary EDTA on the mineral contents of some tissues of Coturnix Coturnix Japonica. Poultry Sci. 1970; 49:565-568. (NA41)

194. Vozar L, Bobek P. The influence of complexon 3 on the composition of the blood serum protein spectrum in rats and guinea pigs. Pharmazie. 1958; 13:704-707. (CA53:12473d)

195. Vohra P, Heil JR. Growth-promoting properties of crude soybean phospholipids. Poultry Sci. 1969; 48(5):1661-1667. (CA72)

196. Will JJ, Vilter RW. The absorption and utilization of an iron chelate in iron-deficient patients. J Lab. Clin. Med. 1954; 44:499-505. (CA49:1961g) Ferric sodium ethylenediaminetetraacetate (I) was given orally, and the absorption and utilization were compared with oral FeSO4 (II). I and II were labeled with isotopic Fe. I was absorbed to the same extent as II (about 6%). No detectable amt. was excreted in the urine. I and II produced identical reticulocyte responses. The observations suggested that I is split in the gastrointestinal tract into ionized Fe and that this is absorbed in the usual manner.

197. Yokel RA, Kostenbauder HB. Assessment of potential aluminum chelators in an octanol/aqueous system and in the aluminum-loaded rabbit. Toxicol. Appl. Pharmacol. 1987; 91(2):281-294. (CA)

198. Zizine LA. Action of a chelating agent on thyroid activity of the rat. Compt. Rend. Soc. Biol. 1958; 152:31-35. (CA52:20623a) Addn. of 0.5% of di-Na Ca ethylenediaminetetraacetate to the diet of rats resulted in a significant decrease in activity of the thyroid.

199. Zarembski PM, Hodgkinson A. Factors influencing the urinary excretion of oxalic acid in man. Clin. Chim. Acta. 1969; 25(1):1-10. (CA71)

200. Zorina LA, Vanshtein IA. Therapeutic value of complexing compounds in chronic lead poisoning. Gigiena Truda Professional'nye Zabolevaniya 3. 1959; 1:7-11. (2085)

201. Zambrano A, Mangieri A, Silvestroni A. Calcium salt of versene in experimental lead poisoning. (Urinary and fecal lead excretion. Electrolytes and alkaline phosphatase in the blood). Folia Medica (Naples). 1955; 38:813-837 (Aug.). (655)

202. Parks PF, Salmon WD. An evaluation of factors affecting survival of choline deficient weaning rats with special emphasis on dietary sodium. J Nutr. 1967; 91(3): part I, 307-313. (CA67)

203. Morgan JM. Chelation therapy in lead nephropathy. South Med. J. 1975; 68:1001-1006. (CA)

204. Oberleas D, Muhrer ME, O'Dell BL. Dietary metal-complexing agents and zinc availability in the rat. J Nutr. 1966; 90:56-62. (NA37)

205. O'Dell BL, Emery M, Xia J, Browning JD. In vitro addition of glutathione to blood from zinc-deficient rats corrects platelet defects: impaired aggregation and calcium uptake. J Nutr. Biochem. 1997; 8(6):346-350. (CA)

206. Parigi A, Giovanelli E. Side effects of oral treatment with CaNa2EDTA. Lavoro e Medicina 16. 1962; 3:48-51. (2451)

207. Owen AA, Peo Jr ER, Cunningham PJ, Moser BD. Effect of EDT on utilization of dietary zinc by G-F swine. J Animal Sci. 1973; 37(2):470-478. (NA44)

208. Aabakken L. 51Cr-Ethylenediaminetetraaceteic acid absorption test. Methodologic aspects. Scand. J Gastroenterol. 1989; 24:351-358.

209. Abels J, Woldring MG, Nieweg HO, Faber JG, de Vries JA. Ethylenediaminetetraacetate (EDTA) and the intestinal absorption of vitamin B12. Nature. 1959; 183:1395-1396. (CA55:1839e)

210. Albahary C. Prevention of lead poisoning. Third World Congress on the Prevention of Occupational Risks, Paris, France. 1961;491. (2222)

211. Alberts JC, Lang JA, Reyes PS, Briggs GM (Dept. Nutr. Sci., Univ. California, Berkeley). Zinc requirement of the young guinea pig. J Nutr. 1977; 107(8):1517-1527. (CA)

212. Ali RAM, Evans JL (Rutgers State Univ., New Brunswick, NJ). Body composition in the growing rat as affected by dietary lactose, calcium, buffering capacity and EDTA. J Anim. Sci. 1971; 33(4):765-770. (CA76)

213. Ali R, Evans JL (Coll. Agr. Cairo Univ., Giza, UAR). Effect of dietary calcium buffering capacity, lactose and EDTA on pH of and calcium absorption from gastrointestinal segments in the growing rat. J Nutr. 1967; 93(3):273-279. (BA49)

214. Mohamed-Ali RA (Rutgers State Univ., New Brunswick, NJ). Effects of dietary calcium level, buffering capacity, lactose, and EDTA (ethylenediaminetetraacetic acid) on calcium metabolism in the growing rat. Diss. Abstr. B. 1967; 27(11):3776-3777. University Microfilms (Ann Arbor, Mich.), Order No. 67-5271, 161 pp. (CA68)

215. Amery WK, Forget PP. The role of the gut in migraine: the oral 51-Cr EDTA test in recurrent abdominal pain. Cephalalgia. 1989; 9:227-229.

216. Alsmeyer WL. Influence of salts of ethylenediaminetetraacetic acid on the tryptophan load test in pyridoxine-deficient swine. Diss. Abstr. B. 1967; 27(11):3730. Univ. Microfilms (Ann Arbor, Mich.), Order No. 67-6541, 99 pp.

217. Anderson WA, Cole MB, Gould GW, Jones MV. Antibacterial food additives for prevention of growth of Listeria and other bacteria. Eur. Pat. Appl. EP 466,244 (Cl. A23L3/3571), 15 Jan 1992, EP Appl. 90/307,694, 13 Jul 1990; 13 pp. (CA)

218. Anon. Avoid "chelation therapy" pills. FDA Consumer. Sept. 1985:19(7):34.

219. Anon. Calcium disodium ethylenediaminetetraacetate: permitted addition to certain foods. Federal Register. 1960; 25:7316. (CA54:25345b)

220. Anon. Black-eye peas, potatoes: order listing disodium EDTA and calcium disodium EDTA as optional ingredients. Federal Register, cf. CA 61, 12544d. Nov. 1964; 29:14984-14985. (CA62: 3316c)

221. Anon. The complexities of EDTA. Food Cosmet. Toxicol. 1972; 10:697-700.

222. Anon. Disodium EDTA (Disodium ethylenediaminetetraacetate). Federal Register, cf. CA 57, 12964d. Nov. 1962; 27:11257. (CA58:3821f) [The previous regulation under the Federal Food, Drug, and Cosmetic Act is extended to permit the use of a max. of 100 p.p.m. of the title compd. as a color preservative in frozen white potatoes.]

223. Anon. Dressings for foods. Food additives. Calcium disodium ethylenediamine-tetraacetate, disodium ethylenediaminetetraacetate; order affecting nomenclature and listing as optional ingredients of mayonnaise, french dressing, and salad dressing. Oleomargarine; order amending identity standard to permit calcium disodium ethylenediaminetetraacetate as optional preservative ingredient. Federal Register cf. CA 55, 14742f; 58, 3821f, 59, 14495d. Feb. 12, 1964; 29:2382-2384. (CA60:13801c)

224. Anon. Food additives. Boiler water additives. Federal Register, cf. CA 58, 10661b. Oct. 16, 1964; 29:14224. (16697c) [Tetrasodium EDTA may be used under the Federal Food, Drug and Cosmetic Act as a boiler water additive in the prepn. of steam that will contact food.]

225. Anon. Food additives. Adhesives. Federal Register, CF. ca 59, 13261c. Dec. 31, 1963; 28:14493. (CA60:6131a) [The previous regulation under the Federal Food, Drug, and Cosmetic Act is revised to permit the use of ferric salts of ethylenediaminetetraacetic acid in food-packaging adhesives.]

226. Anon. Food additives. Calcium disodium EDTA. Federal Register, cf. CA 62, 3316c. May 21, 1965; 30:6915-6916. (CA63:6236e) [The previous regulation under the Federal Food, Drug, and Cosmetic Act was revised to provide for the use of a max. of 310 ppm. of Ca di-Na EDTA as a color stabilizer in canned, cooked, and dried lima beans.]

227. Anon. Food additives. Calcium disodium EDTA. Federal Register, cf. CA 55. August 29, 1961; 26:8072. (CA55:23853h) [One hundred p.p.m. of the title compd. may be used under the Food, Drug, and Cosmetic Act in pecan pie fillings to prevent discoloration.]

228. Anon. Food additives. Calcium disodium ethylenediaminetetraacetate. Federal Register, cf. CA 55, 4811c. Apr. 4, 1961; 26:2780. (CA55:10737c) [The previous regulations under the Food, Drug, and Cosmetic Act are revised to permit 275 p.p.m. of the title compd. (calcd. a